Howard Bailey

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. ncbi request reprint Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma
    Howard H Bailey
    University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    Cancer 107:2462-7. 2006
  2. ncbi request reprint Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors
    Howard H Bailey
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    Clin Cancer Res 13:3623-9. 2007
  3. pmc A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer
    Howard H Bailey
    University of Wisconsin Paul P Carbone Cancer Center, Madison, USA
    Cancer Prev Res (Phila) 3:35-47. 2010
  4. ncbi request reprint A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma
    Sherry Morgan-Meadows
    University of Wisconsin Comprehensive Cancer Center, Madison, WI 53792, USA
    Oncology 69:130-4. 2005
  5. doi request reprint A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors
    William Schelman
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, 600 Highland Avenue, K4 530 CSC, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 62:727-33. 2008
  6. ncbi request reprint Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer
    Glenn Liu
    University of Wisconsin Comprehensive Cancer Center, Madison, WI 53792, USA
    Invest New Drugs 21:367-72. 2003
  7. pmc Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design
    Amye Tevaarwerk
    University of Wisconsin Carbone Cancer Center, Madison, WI, USA
    Invest New Drugs 30:1039-45. 2012
  8. ncbi request reprint Phase I trial of perillyl alcohol administered four times daily continuously
    Sherry Morgan-Meadows
    University of Wisconsin Comprehensive Cancer Center, 600 Highland Ave K4 601, Madison, Wisconsin 53792, USA
    Cancer Chemother Pharmacol 52:361-6. 2003
  9. pmc Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin
    Jason Gee
    University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA
    Prostate 73:970-8. 2013
  10. ncbi request reprint Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer
    Sherry Morgan Meadows
    Department of Medicine, Division of Medical Oncology, The University of Wisconsin, Madison, WI, USA
    Int J Gastrointest Cancer 32:125-8. 2002

Collaborators

Detail Information

Publications28

  1. ncbi request reprint Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma
    Howard H Bailey
    University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    Cancer 107:2462-7. 2006
    ....
  2. ncbi request reprint Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors
    Howard H Bailey
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    Clin Cancer Res 13:3623-9. 2007
    ..To assess the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacodynamics, and antitumor activity of continuous weekly-administered paclitaxel and BMS-214662, a novel farnesyl transferase inhibitor...
  3. pmc A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer
    Howard H Bailey
    University of Wisconsin Paul P Carbone Cancer Center, Madison, USA
    Cancer Prev Res (Phila) 3:35-47. 2010
    ..069) in new NMSC that was predominantly due to a marked reduction in new BCC. Based on these data, the potential of DFMO, alone or in combination, to prevent skin cancers should be explored further...
  4. ncbi request reprint A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma
    Sherry Morgan-Meadows
    University of Wisconsin Comprehensive Cancer Center, Madison, WI 53792, USA
    Oncology 69:130-4. 2005
    ..The aim of this study was to evaluate the overall response rate, toxicity and overall survival in patients with locally advanced or metastatic esophageal cancer treated with gemcitabine, 5-fluorouracil (5-FU) and leucovorin...
  5. doi request reprint A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors
    William Schelman
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, 600 Highland Avenue, K4 530 CSC, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 62:727-33. 2008
    ..We conducted a phase I trial to assess the maximum tolerated dose, dose limiting toxicity (DLT) and antitumor activity of gemcitabine and patupilone...
  6. ncbi request reprint Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer
    Glenn Liu
    University of Wisconsin Comprehensive Cancer Center, Madison, WI 53792, USA
    Invest New Drugs 21:367-72. 2003
    ..Secondary objectives included assessing acute and chronic toxicities, as well as measuring objective response rates...
  7. pmc Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design
    Amye Tevaarwerk
    University of Wisconsin Carbone Cancer Center, Madison, WI, USA
    Invest New Drugs 30:1039-45. 2012
    ..The primary objectives were to determine the maximum tolerated dose (MTD) and response of continuous MKC-1. Secondary objectives included characterizing the dose limiting toxicities (DLTs) and pharmacokinetics (PK)...
  8. ncbi request reprint Phase I trial of perillyl alcohol administered four times daily continuously
    Sherry Morgan-Meadows
    University of Wisconsin Comprehensive Cancer Center, 600 Highland Ave K4 601, Madison, Wisconsin 53792, USA
    Cancer Chemother Pharmacol 52:361-6. 2003
    ..Therefore, a new formulation of POH was developed (700 mg containing 675 mg POH) in an effort to improve dose and metabolite concentrations delivered and toxicity encountered with chronic dosing...
  9. pmc Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin
    Jason Gee
    University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA
    Prostate 73:970-8. 2013
    ..Here, we evaluate the biologic activity of a less calcemic vitamin D analog 1α-hydroxyvitamin D2 [1α-OH-D2] (Bone Care International, Inc.) in patients with prostate cancer and high grade prostatic intraepithelial neoplasia (HG PIN)...
  10. ncbi request reprint Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer
    Sherry Morgan Meadows
    Department of Medicine, Division of Medical Oncology, The University of Wisconsin, Madison, WI, USA
    Int J Gastrointest Cancer 32:125-8. 2002
    ..This is a phase II study of perillyl alcohol in the treatment of patients with metastatic colorectal carcinoma. The primary endpoint is time to progression. Secondary objectives are to evaluate objective response rate and toxicity...
  11. pmc The Wisconsin Network for Health Research (WiNHR): a statewide, collaborative, multi-disciplinary, research group
    Howard Bailey
    University of Wisconsin School of Medicine and Public Health, Madison 53792, USA
    WMJ 108:453-8. 2009
    ..This optimism is based on the relevance of its goals to public health, the quality of statewide health care research, and, most importantly, the residents of Wisconsin who recognize the value of health research...
  12. pmc The differential diagnosis of pulmonary blastomycosis using case vignettes: a Wisconsin Network for Health Research (WiNHR) study
    Dennis J Baumgardner
    Department of Family Medicine, University of Wisconsin School of Medicine and Public Health, Milwaukee, USA
    WMJ 110:68-73. 2011
    ..This study addressed the diagnostic accuracy of physicians responding to case vignettes of pulmonary blastomycosis and the primary care differential diagnosis of this disease...
  13. pmc Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
    Anne M Traynor
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, WI 53792, USA
    Invest New Drugs 29:316-22. 2011
    ..To assess the safety, maximum-tolerated dose (MTD), and dose-limiting toxicities (DLT), of motexafin gadolinium (MGd), given in combination with doxorubicin, in patients with advanced solid tumors...
  14. ncbi request reprint Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer
    Howard H Bailey
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, 600 Highland Avenue K4 6 CSC, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 62:149-57. 2008
    ..We conducted a phase II multi-institutional study of oral POH administered four times daily in women with advanced treatment-refractory breast cancer...
  15. ncbi request reprint Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial
    David M Kushner
    Division of Gynecologic Oncology, University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, and Regional Cancer Center at Oconomowoc Waukesha Memorial Hospitals, WI, USA
    Gynecol Oncol 105:358-64. 2007
    ..The optimal specific combination has yet to be determined. The current study evaluates weekly docetaxel and carboplatin in this setting...
  16. pmc Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies
    Steven Attia
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center Madison, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 64:45-51. 2009
    ..To define dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of capecitabine with fixed-dose rate (FDR) gemcitabine...
  17. ncbi request reprint A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96
    Howard H Bailey
    University of Wisconsin Madison, Madison, Wisconsin 53792, USA
    Gynecol Oncol 85:464-8. 2002
    ..Perillyl alcohol was administered orally, four times daily, at a dose of 1200 mg/m(2). This was repeated until disease progression or unacceptable toxicity was experienced...
  18. ncbi request reprint Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study
    Brad S Kahl
    Department of Medicine, University of Wisconsin Comprehensive Cancer Center, University of Wisconsin Medical School, Madison, WI 53792, USA
    Cancer Invest 23:13-8. 2005
    ..The response rate appears similar to other reports using different doses and schedules. Myelosuppression appears less with this schedule than with other schedules...
  19. ncbi request reprint Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol
    James P Thomas
    University of Wisconsin Comprehensive Cancer Center, University of Wisconsin Medical School, 600 Highland Ave, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 50:465-72. 2002
    ..We conducted a phase I trial and pharmacokinetic study of flavopiridol given as a 72-h continuous intravenous infusion repeated every 2 weeks...
  20. ncbi request reprint A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days
    Howard H Bailey
    University of Wisconsin Comprehensive Cancer Center, K6 568 CSC, 600 Highland Avenue, Madison, WI 53792 5669, USA
    Cancer Chemother Pharmacol 54:368-76. 2004
    ..A phase I study of POH for 14 days out of every 28 days in subjects with advanced malignancies was performed to evaluate dose escalation, toxicity, pharmacokinetics, and effects on TGFbeta and Ras...
  21. ncbi request reprint Gemcitabine, Paclitaxel, and piritrexim: a phase I study
    Glenn Liu
    University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, USA
    Am J Clin Oncol 26:280-4. 2003
    ..The combination of these new antifolates with paclitaxel and gemcitabine appears safe and should be considered for phase II trials in known responsive tumors such as transitional cell carcinomas...
  22. pmc Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome
    Adam Petrich
    Department of Medicine, University of Wisconsin Comprehensive Cancer Center, University of Wisconsin, Madison, WI, USA
    Leuk Lymphoma 49:57-61. 2008
    ..Overall the treatment was well tolerated. One patient was removed from study due to hypercalcemia. We conclude that short-term treatment with doxercalciferol has limited activity in patients with MDS...
  23. ncbi request reprint Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy
    Sherry Morgan-Meadows
    University of Wisconsin Comprehensive Cancer Center, Madison 53792, USA
    Invest New Drugs 20:377-82. 2002
    ..The objectives of this trial were to assess the maximal tolerated dose and toxicity of the combination of oral eniluracil and 5-fluorouracil and intravenous gemcitabine...
  24. ncbi request reprint Non-Hodgkin's lymphoma presenting as a pelvic mass with elevated CA-125
    Gregory W Allen
    Department of Human Oncology, University of Wisconsin Hospital and Clinics, Madison, WI 53792, USA
    Gynecol Oncol 94:811-3. 2004
    ..A review of the literature is presented and a possible mechanism for CA-125 elevation in diseases other than ovarian cancer is discussed...
  25. ncbi request reprint Progress of a Comprehensive Familial Cancer Genetic Counseling Program in the Era of BRCA1 and BRCA2
    Ellen M Hartenbach
    University of Wisconsin Comprehensive Cancer Center, Gynecologic Oncology Program, Madison 53792, USA
    Genet Test 6:75-8. 2002
    ..In our program, the majority of families counseled were eligible for BRCA1/BRCA2 testing, but only 18% have elected to proceed at this time...
  26. ncbi request reprint Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer
    Glenn Liu
    University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    Clin Cancer Res 8:2820-7. 2002
    ..Whereas the defined maximum tolerated dose was not reached, the recommended Phase II dose was 12.5 microg/day given continuously...
  27. ncbi request reprint Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer
    Glenn Liu
    Department of Medicine, Medical Oncology Section, University of Wisconsin Comprehensive Cancer Center, 600 Highland Avenue, Madison, WI 53792, USA
    Clin Cancer Res 9:4077-83. 2003
    ..Given the cytostatic nature of the drug, the primary study end point was progression-free survival for a minimum of 6 months. The secondary end point was further characterization of drug toxicity...
  28. ncbi request reprint A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study
    Deborah K Armstrong
    John Hopkins Kimmel Cancer Center, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231 1000, USA
    Gynecol Oncol 103:391-6. 2006
    ..The goals of this phase I study were to determine the maximum tolerated dose (MTD) of IP paclitaxel microspheres and the pharmacology of paclitaxel after IP paclitaxel microsphere administration...

Research Grants6

  1. DFMO Prevention Study (2b) in Organ Transplant Subjects
    Howard Bailey; Fiscal Year: 2002
    ..abstract_text> ..
  2. DFMO Prevention Study (2b) in Organ Transplant Subjects
    Howard Bailey; Fiscal Year: 2003
    ..abstract_text> ..
  3. Chemoprevention of Skin Cancer - DFMO Phase III Trial
    Howard Bailey; Fiscal Year: 2004
    ..Ototoxicity and gastrointestinal toxicity have been most common). The objectives, which are unchanged from our original proposal, are all on schedule to be completed in the next 1-2 years. ..
  4. DFMO Prevention Study (2b) in Organ Transplant Subjects
    Howard Bailey; Fiscal Year: 2004
    ..abstract_text> ..
  5. Chemoprevention of Skin Cancer - DFMO Phase III Trial
    Howard Bailey; Fiscal Year: 2005
    ..Ototoxicity and gastrointestinal toxicity have been most common). The objectives, which are unchanged from our original proposal, are all on schedule to be completed in the next 1-2 years. ..
  6. DFMO Prevention Study (2b) in Organ Transplant Subjects
    Howard Bailey; Fiscal Year: 2005
    ..abstract_text> ..